Business Segments · Operating Income (Loss)
Life Sciences Solutions — Operating Income (Loss)
Thermo Fisher Scientific Life Sciences Solutions — Operating Income (Loss) decreased by 48.8% to $954M in Q1 2026 compared to the prior quarter. Year-over-year, this metric declined by 44.4%, from $1.72B to $954M. This decline may warrant attention — for this metric, higher values are generally preferred.
Analysis
StatementSegment
CategoryProfitability
SignalHigher is better
VolatilityStable
First reportedQ1 2013
Last reportedQ1 2026May 1, 2026
Rolls up toOperating Income
How to read this metric
An increase indicates improved profitability and operational efficiency, while a decrease signals margin compression or rising costs.
Detailed definition
The profit generated by the Life Sciences Solutions segment after deducting all operating expenses, including COGS, SG&A...
Peer comparison
The primary metric for evaluating the performance of any business segment.
Metric ID:
tmo_segment_life_sciences_solutions_operating_income_lossHistorical Data
37 periods
| Q2 '21 | Q2 '21 | Q3 '21 | Q3 '21 | Q4 '21 | Q4 '21 | Q1 '22 | Q1 '22 | Q2 '22 | Q2 '22 | Q3 '22 | Q3 '22 | Q4 '22 | Q4 '22 | Q1 '23 | Q1 '23 | Q2 '23 | Q2 '23 | Q3 '23 | Q3 '23 | Q4 '23 | Q4 '23 | Q1 '24 | Q1 '24 | Q2 '24 | Q2 '24 | Q3 '24 | Q3 '24 | Q4 '24 | Q4 '24 | Q1 '25 | Q1 '25 | Q2 '25 | Q3 '25 | Q4 '25 | Q1 '26 | Q1 '26 | |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Value | $2.16B | $1.72B | $2.28B | $1.82B | $2.54B | $2B | $2.82B | $2.18B | $2B | $1.33B | $1.71B | $1.04B | $1.86B | $1.04B | $1.56B | $836M | $1.58B | $817M | $1.86B | $872M | $1.85B | $895M | $1.66B | $840M | $1.82B | $865M | $1.84B | $845M | $2.02B | $952M | $1.72B | $834M | $920M | $968M | $1.05B | $1.86B | $954M |
| QoQ Change | — | -20.6% | +32.6% | -20.1% | +39.4% | -21.2% | +41.1% | -22.9% | -8.0% | -33.7% | +28.9% | -39.2% | +79.1% | -44.1% | +50.3% | -46.5% | +88.8% | -48.2% | +128.2% | -53.2% | +112.6% | -51.7% | +85.8% | -49.5% | +116.7% | -52.5% | +112.5% | -54.0% | +138.6% | -52.8% | +80.3% | -51.4% | +10.3% | +5.2% | +8.1% | +78.1% | -48.8% |
| YoY Change | — | — | — | — | — | — | — | — | -7.5% | -38.7% | -24.9% | -54.4% | -26.7% | -59.0% | -44.6% | -70.4% | -21.1% | -59.2% | +9.0% | -49.0% | -0.4% | -51.9% | +6.4% | -46.3% | +15.3% | -45.2% | -1.4% | -54.7% | +8.7% | -48.7% | +3.2% | -49.8% | -49.5% | -47.3% | -48.1% | +8.6% | -44.4% |
Range$817M – $2.82B
CAGR-8.7%
Avg YoY Growth-30.8%
Median YoY Growth-44.6%
Similar Metrics at Other Companies
Frequently Asked Questions
- What is Thermo Fisher Scientific's life sciences solutions — operating income (loss)?
- Thermo Fisher Scientific (TMO) reported life sciences solutions — operating income (loss) of $954M in Q1 2026.
- How has Thermo Fisher Scientific's life sciences solutions — operating income (loss) changed year-over-year?
- Thermo Fisher Scientific's life sciences solutions — operating income (loss) decreased by 44.4% year-over-year, from $1.72B to $954M.
- What does life sciences solutions — operating income (loss) mean?
- The profit earned from the segment's core business operations before interest and taxes.